2689-47-6

Basic information

• Product Name: 3-acetylphenyl dimethylcarbamate
• Synonyms: 3-acetylphenyl dimethylcarbamate
• CAS NO: 2689-47-6
• Molecular Formula: C₁₁H₁₃NO₃
• Molecular Weight: 207.22582
• Mol File: 2689-47-6.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 135-136 °C(Press: 0.7 Torr)
• Appearance: /
• Density: 1.136±0.06 g/cm3(Predicted)
• PKA: -1.56±0.70(Predicted)
• CAS DataBase Reference: 3-acetylphenyl dimethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-acetylphenyl dimethylcarbamate(2689-47-6)
• EPA Substance Registry System: 3-acetylphenyl dimethylcarbamate(2689-47-6)

Safety Data

• Hazardous Substances Data: 2689-47-6(Hazardous Substances Data)

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 79-44-7 N,N-Dimethylcarbamoyl chloride 

Downstream Products

• 444645-98-1 3-[3-(4-trifluoromethyl)phenyl]acryloylphenyl dimethylcarbamate 

Relevant articles and documents

Design, synthesis and biological evaluation of novel carbamates as potential inhibitors of acetylcholinesterase and butyrylcholinesterase

Rivastigmine, a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), has been approved by U.S. Food and Drug Administration to treat Alzheimer's disease (AD) and Parkinson's disease (PD) dementia. In the current work, a bambuterol derivative lacking one of the carbamoyloxy groups on the benzene ring (BMC-1) and its analogues were synthesized using 1-(3-hydroxyphenyl) ethan-1-one and 1-(4-hydroxyphenyl) ethan-1-one as starting materials. In-vitro cholinesterase assay established that nine compounds were more potent to inhibit both electric eel AChE and equine serum BChE than rivastigmine under the same experimental conditions. Further study confirmed that among the nine carbamates, BMC-3 (IC50(AChE) = 792 nM, IC50(BChE) = 2.2 nM) and BMC-16 (IC50(AChE) = 266 nM, IC50(BChE) = 10.6 nM) were excellent cholinesterase inhibitors with potential of permeating through the blood-brain barrier. These carbamates could be used as potential dual inhibitors of AChE and BChE and to discover novel drugs for the treatment of AD and PD dementia.

Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors

A series of novel chalcone-rivastigmine hybrids were designed, synthesized, and tested in vitro for their ability to inhibit human acetylcholinesterase and butyrylcholinesterase. Most of the target compounds showed hBChE selective activity in the micro- a

A kind of carbamate-koncar ketone choline esterase inhibitor and its preparation method and application (by machine translation)

The present invention discloses a kind of carbamate-koncar ketone choline esterase inhibitor and its preparation method and application, belongs to the field of medicinal chemistry. Cholinesterase inhibitors of the invention represented by general formula